Titan Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $81 | $0 | $4 |
Gross Profit | -3 | -2 | -23 | |
EBITDA | -2,071 | -1,061 | -2,034 | |
EBIT | -2,074 | -1,063 | -2,061 | |
Net Income | -2,093 | -1,060 | -1,970 | -338 |
Net Change In Cash | 0 | 81 | 0 | 4 |
Free Cash Flow | -2,068 | -613 | -2,248 | -1,835 |
Cash | 4,091 | 6,773 | 6,760 | 8,096 |
Basic Shares | 914 | 7,815 | 7,533 | 7,508 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $184 | $60 | $1,526 | $4,838 |
Gross Profit | -1,729 | -136 | 1,327 | 4,366 |
EBITDA | -7,165 | -10,039 | -9,133 | -7,059 |
EBIT | -7,277 | -10,235 | -9,354 | -7,351 |
Net Income | -5,569 | -10,177 | -8,114 | -20,728 |
Net Change In Cash | 184 | 60 | 1,526 | 4,838 |
Cost of Revenue | 190 | |||
Free Cash Flow | -7,094 | -8,183 | -7,922 | -17,743 |
Cash | 6,760 | 2,937 | 6,037 | 5,413 |
Basic Shares | 752 | 671 | 486 | 188 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$2.28 |
2024-03-31 | -$1.24 |
2023-12-31 | -$2.52 |
2023-09-30 | -$0.02 |
